BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18497949)

  • 21. Induction of anergy in human T helper 0 cells by stimulation with altered T cell antigen receptor ligands.
    Tsitoura DC; Holter W; Cerwenka A; Gelder CM; Lamb JR
    J Immunol; 1996 Apr; 156(8):2801-8. PubMed ID: 8609399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA class I-restricted recognition of an HIV-derived epitope peptide by a human T cell receptor alpha chain having a Vdelta1 variable segment.
    Ueno T; Tomiyama H; Fujiwara M; Oka S; Takiguchi M
    Eur J Immunol; 2003 Oct; 33(10):2910-6. PubMed ID: 14515275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.
    Castelli FA; Leleu M; Pouvelle-Moratille S; Farci S; Zarour HM; Andrieu M; Auriault C; Ménez A; Georges B; Maillere B
    Eur J Immunol; 2007 Jun; 37(6):1513-23. PubMed ID: 17492804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MHC class II binding of peptides derived from HLA-DR 1.
    Harris PE; Liu Z; Suciu-Foca N
    J Immunol; 1992 Apr; 148(7):2169-74. PubMed ID: 1545124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
    Mittendorf EA; Gurney JM; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Surgery; 2006 Mar; 139(3):407-18. PubMed ID: 16546506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.
    Berthelot L; Laplaud DA; Pettré S; Ballet C; Michel L; Hillion S; Braudeau C; Connan F; Lefrère F; Wiertlewski S; Guillet JG; Brouard S; Choppin J; Soulillou JP
    Eur J Immunol; 2008 Jul; 38(7):1889-99. PubMed ID: 18506883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis.
    Penzotti JE; Doherty D; Lybrand TP; Nepom GT
    J Autoimmun; 1996 Apr; 9(2):287-93. PubMed ID: 8738976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited plasticity in T cell recognition of modified T cell receptor contact residues in MHC class II bound peptides.
    de Haan EC; Wagenaar-Hilbers JP; Liskamp RM; Moret EE; Wauben MH
    Mol Immunol; 2005 Feb; 42(3):355-64. PubMed ID: 15589324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation.
    Chen YZ; Matsushita S; Nishimura Y
    J Immunol; 1996 Nov; 157(9):3783-90. PubMed ID: 8892606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
    Tsuda N; Chang DZ; Mine T; Efferson C; García-Sastre A; Wang X; Ferrone S; Ioannides CG
    Cancer Res; 2007 Sep; 67(17):8378-87. PubMed ID: 17804754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen.
    Hess AD; Thoburn CJ; Miura Y; Bright EC
    Clin Immunol; 2005 Mar; 114(3):307-19. PubMed ID: 15721842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells.
    Hedlund G; Dohlsten M; Herrmann T; Buell G; Lando PA; Segrén S; Schrimsher J; MacDonald HR; Sjögren HO; Kalland T
    J Immunol; 1991 Dec; 147(12):4082-5. PubMed ID: 1753087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
    Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
    Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
    Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
    J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.